Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC

7166 Background: Previous NSCLC trials have suggested female non-smokers with adenocarcinoma are most likely to benefit from treatment with EGFR inhibitors such as erlotinib. Thus, male smokers wit...